|
|
Article: Chiron's Failed Sepsis Drug Taking On CAP In Phase III.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
National Editor
As expected, Chiron Corp. started its Phase III trial testing tifacogin, a recombinant tissue factor pathway inhibitor, against severe community-acquired pneumonia (CAP).
Tifacogin, which was developed by Chiron and in November 2001 became one of many drugs defeated by sepsis, goes up against CAP in a randomized, placebo-controlled study - one that, if successful, likely will lead Chiron to ask for a sepsis label, said Craig West, analyst with A.G. Edwards in St. Louis.
"Everybody would do that," West said. "It's a no-brainer. You always ask for the broadest thing."
The company's stock (NASDAQ:CHIR) dipped 50 cents ...